Healthcare provider profile · identity verified

Milagro D. Ramos, MD

Family Practice · BELLFLOWER, CA · NPI 1891854428

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	669	347
Lisinopril	Lisinopril	306	168
Amlodipine Besylate	Amlodipine Besylate	282	151
Metformin Hcl	Metformin Hcl	272	153
Losartan Potassium	Losartan Potassium	259	149
Rosuvastatin Calcium	Rosuvastatin Calcium	256	142
Glipizide	Glipizide	230	121
Gabapentin	Gabapentin	207	122
Omeprazole	Omeprazole	179	126
Alendronate Sodium	Alendronate Sodium	173	89
Levothyroxine Sodium	Levothyroxine Sodium	172	103
Pantoprazole Sodium	Pantoprazole Sodium	121	67
Hydrochlorothiazide	Hydrochlorothiazide	118	73
Meloxicam	Meloxicam	115	79
Atenolol	Atenolol	105	62
Simvastatin	Simvastatin	102	55
Trazodone Hcl	Trazodone Hcl	102	64
Metformin Hcl Er	Metformin Hcl	101	53
Tamsulosin Hcl	Tamsulosin Hcl	90	55
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	83	54
Ibuprofen	Ibuprofen	82	58
Humulin N Kwikpen	Insulin Nph Human Isophane	80	31
Hydralazine Hcl	Hydralazine Hcl	78	39
Albuterol Sulfate Hfa	Albuterol Sulfate	70	54
Mirtazapine	Mirtazapine	70	41
Ozempic	Semaglutide	70	18
Finasteride	Finasteride	67	37
Naproxen	Naproxen	67	44
Sertraline Hcl	Sertraline Hcl	66	39
Hydrocortisone	Hydrocortisone	62	45
Potassium Chloride	Potassium Chloride	61	44
Metoprolol Tartrate	Metoprolol Tartrate	60	34
Escitalopram Oxalate	Escitalopram Oxalate	57	29
Jardiance	Empagliflozin	56	32
Carvedilol	Carvedilol	55	32
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	55	28
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	53	13
Furosemide	Furosemide	52	37
Pradaxa	Dabigatran Etexilate Mesylate	52	29
Triamcinolone Acetonide	Triamcinolone Acetonide	50	38
Bisoprolol Fumarate	Bisoprolol Fumarate	48	23
Ibandronate Sodium	Ibandronate Sodium	45	16
Clonazepam	Clonazepam	44	suppressed
Trospium Chloride	Trospium Chloride	41	25
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	40	suppressed
Tramadol Hcl	Tramadol Hcl	40	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	20
Latanoprost	Latanoprost	35	12
Acetaminophen-Codeine	Acetaminophen With Codeine	34	suppressed
Clopidogrel	Clopidogrel Bisulfate	34	20
Humulin N	Insulin Nph Human Isophane	34	23
Spiriva Respimat	Tiotropium Bromide	34	suppressed
Alprazolam	Alprazolam	32	suppressed
Estradiol	Estradiol	32	20
Fluoxetine Hcl	Fluoxetine Hcl	32	19
Lorazepam	Lorazepam	32	17
Pregabalin	Pregabalin	32	13
Benazepril Hcl	Benazepril Hcl	31	15
Alvesco	Ciclesonide	30	15
Lactulose	Lactulose	29	21
Terazosin Hcl	Terazosin Hcl	29	18
Pravastatin Sodium	Pravastatin Sodium	27	16
Bupropion Xl	Bupropion Hcl	26	11
Duloxetine Hcl	Duloxetine Hcl	26	17
Fenofibrate	Fenofibrate	26	12
Clobetasol Propionate	Clobetasol Propionate	25	13
Donepezil Hcl	Donepezil Hcl	24	14
Prednisone	Prednisone	24	22
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	12
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	24	19
Megestrol Acetate	Megestrol Acetate	23	15
Venlafaxine Hcl Er	Venlafaxine Hcl	23	11
Buspirone Hcl	Buspirone Hcl	22	13
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	11
Wixela Inhub	Fluticasone Propion/Salmeterol	20	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	19	suppressed
Fluconazole	Fluconazole	19	16
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Ketoconazole	Ketoconazole	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Glipizide Er	Glipizide	18	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	16	16
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Flunisolide	Flunisolide	15	12
Glipizide-Metformin	Glipizide/Metformin Hcl	15	suppressed
Humulin R	Insulin Regular, Human	15	suppressed
Nitroglycerin	Nitroglycerin	15	13
Nortriptyline Hcl	Nortriptyline Hcl	15	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	11
Spironolactone	Spironolactone	14	suppressed
Cyclosporine	Cyclosporine	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Metronidazole	Metronidazole	13	12
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	suppressed
Eliquis	Apixaban	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Temazepam	Temazepam	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error